Fact check
“The FDA will consider all information provided in response to this Request for Information (RFI) to inform whether and how these specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.”
Reasoning
The claim references an FDA statement about considering information from an RFI in IND reviews for ibogaine, but no documents or sources were provided to verify this policy or statement.
On confidence: No evidence was supplied to confirm or refute the claim.
Important context
The claim pertains to FDA regulatory procedures regarding ibogaine IND applications, which would require official FDA communications or policy documents for verification.
Evidence
No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.
Limitations
Evaluation is limited to the absence of supplied evidence; without access to FDA notices, guidance, or the specific RFI, the claim cannot be verified.
- Last verified:
- Oct 6, 2026, 4:16 AM CDT
- Pipeline:
- 2.1.0
- Claim type:
- Factual
Where this claim appeared
Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for InformationFederal Register · Drug Administration, Human Services Department, Food, Health